Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo
The vascular endothelial progress issue (VEGF)/VEGF receptor (VEGFR) axis is an important regulator of angiogenesis and vital therapeutic goal in most cancers. Ramucirumab is an anti-VEGFR2 monoclonal antibody used for the therapy of a number of cancers. Elevated circulating VEGF-A … Read More